62 related articles for article (PubMed ID: 21898331)
1. Preparation of HCV NS3 and NS5B proteins to support small-molecule drug discovery.
Hung M; Wang R; Liu X
Curr Protoc Pharmacol; 2011 Sep; Chapter 13():Unit13B.6. PubMed ID: 21898331
[TBL] [Abstract][Full Text] [Related]
2. In vitro selection of RNA aptamers against the HCV NS3 helicase domain.
Nishikawa F; Funaji K; Fukuda K; Nishikawa S
Oligonucleotides; 2004; 14(2):114-29. PubMed ID: 15294075
[TBL] [Abstract][Full Text] [Related]
3. An uniquely purified HCV NS3 protease and NS4A(21-34) peptide form a highly active serine protease complex in peptide hydrolysis.
Sardana VV; Blue JT; Zugay-Murphy J; Sardana MK; Kuo LC
Protein Expr Purif; 1999 Aug; 16(3):440-7. PubMed ID: 10425166
[TBL] [Abstract][Full Text] [Related]
4. A novel recombinant single-chain hepatitis C virus NS3-NS4A protein with improved helicase activity.
Howe AY; Chase R; Taremi SS; Risano C; Beyer B; Malcolm B; Lau JY
Protein Sci; 1999 Jun; 8(6):1332-41. PubMed ID: 10386883
[TBL] [Abstract][Full Text] [Related]
5. Identification of non-macrocyclic small molecule inhibitors against the NS3/4A serine protease of hepatitis C virus through in silico screening.
Chaudhuri R; Lee H; Truong L; Torres J; Patel K; Johnson ME
J Chem Inf Model; 2012 Aug; 52(8):2245-56. PubMed ID: 22697413
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus NS3 RNA helicase activity is modulated by the two domains of NS3 and NS4A.
Kuang WF; Lin YC; Jean F; Huang YW; Tai CL; Chen DS; Chen PJ; Hwang LH
Biochem Biophys Res Commun; 2004 Apr; 317(1):211-7. PubMed ID: 15047170
[TBL] [Abstract][Full Text] [Related]
7. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B
J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995
[TBL] [Abstract][Full Text] [Related]
8. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus.
De Francesco R; Carfí A
Adv Drug Deliv Rev; 2007 Oct; 59(12):1242-62. PubMed ID: 17869377
[TBL] [Abstract][Full Text] [Related]
9. High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors.
Lee JC; Yu MC; Lien TW; Chang CF; Hsu JT
Assay Drug Dev Technol; 2005 Aug; 3(4):385-92. PubMed ID: 16180993
[TBL] [Abstract][Full Text] [Related]
10. Optimization of the multiple enzymatic activities of the hepatitis C virus NS3 protein.
Misialek S; Rajagopalan R; Stevens SK; Beigelman L; Seiwert SD; Kossen K
Anal Biochem; 2009 Nov; 394(1):138-40. PubMed ID: 19591800
[TBL] [Abstract][Full Text] [Related]
11. High-throughput screening assay of hepatitis C virus helicase inhibitors using fluorescence-quenching phenomenon.
Tani H; Akimitsu N; Fujita O; Matsuda Y; Miyata R; Tsuneda S; Igarashi M; Sekiguchi Y; Noda N
Biochem Biophys Res Commun; 2009 Feb; 379(4):1054-9. PubMed ID: 19150342
[TBL] [Abstract][Full Text] [Related]
12. Preparation and handling of hepatitis C viral proteins NS3 and NS5B for structural studies.
Marco SD; Carfí A
Methods Mol Biol; 2009; 510():111-24. PubMed ID: 19009257
[TBL] [Abstract][Full Text] [Related]
13. Structure-based discovery of triphenylmethane derivatives as inhibitors of hepatitis C virus helicase.
Chen CS; Chiou CT; Chen GS; Chen SC; Hu CY; Chi WK; Chu YD; Hwang LH; Chen PJ; Chen DS; Liaw SH; Chern JW
J Med Chem; 2009 May; 52(9):2716-23. PubMed ID: 19419203
[TBL] [Abstract][Full Text] [Related]
14. Modulation of hepatitis C virus NS3 protease and helicase activities through the interaction with NS4A.
Gallinari P; Paolini C; Brennan D; Nardi C; Steinkühler C; De Francesco R
Biochemistry; 1999 Apr; 38(17):5620-32. PubMed ID: 10220351
[TBL] [Abstract][Full Text] [Related]
15. Establishment and application of high throughput screening model for hepatitis C virus NS3-4A protease inhibitors in vitro.
Jian-rui L; Yan-bin W; Shu-yi S; Hong-shan C; Jian-dong J; Zong-gen B
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Feb; 33(1):98-101. PubMed ID: 21375947
[TBL] [Abstract][Full Text] [Related]
16. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
Tsantrizos YS
Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
[TBL] [Abstract][Full Text] [Related]
17. Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors.
Musmuca I; Caroli A; Mai A; Kaushik-Basu N; Arora P; Ragno R
J Chem Inf Model; 2010 Apr; 50(4):662-76. PubMed ID: 20225870
[TBL] [Abstract][Full Text] [Related]
18. Complex formation of NS5B with NS3 and NS4A proteins of hepatitis C virus.
Ishido S; Fujita T; Hotta H
Biochem Biophys Res Commun; 1998 Mar; 244(1):35-40. PubMed ID: 9514871
[TBL] [Abstract][Full Text] [Related]
19. Serine protease of hepatitis C virus expressed in insect cells as the NS3/4A complex.
Sali DL; Ingram R; Wendel M; Gupta D; McNemar C; Tsarbopoulos A; Chen JW; Hong Z; Chase R; Risano C; Zhang R; Yao N; Kwong AD; Ramanathan L; Le HV; Weber PC
Biochemistry; 1998 Mar; 37(10):3392-401. PubMed ID: 9521660
[TBL] [Abstract][Full Text] [Related]
20. Designing and analysis of a potent bi-functional aptamers that inhibit protease and helicase activities of HCV NS3.
Umehara T; Fukuda K; Nishikawa F; Sekiya S; Kohara M; Hasegawa T; Nishikawa S
Nucleic Acids Symp Ser (Oxf); 2004; (48):195-6. PubMed ID: 17150545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
